Several analysts have recently updated their ratings and price targets for OptiNose (NASDAQ: OPTN):

  • 11/7/2017 – OptiNose is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $29.00 price target on the stock.
  • 11/7/2017 – OptiNose is now covered by analysts at Jefferies Group LLC. They set a “buy” rating and a $27.00 price target on the stock.
  • 11/7/2017 – OptiNose is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $27.00 price target on the stock.
  • 11/7/2017 – OptiNose is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $33.00 price target on the stock.

OptiNose, Inc. (OPTN) traded up $1.61 during midday trading on Thursday, hitting $18.46. The company’s stock had a trading volume of 82,000 shares, compared to its average volume of 191,411. OptiNose, Inc. has a twelve month low of $15.01 and a twelve month high of $21.46.

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Receive News & Ratings for OptiNose Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose Inc and related companies with MarketBeat.com's FREE daily email newsletter.